Profile data is unavailable for this security.
About the company
Vistin Pharma ASA is a Norway-based holding company, which operates through its subsidiary Vistin Pharma AS. The Company is engaged in the pharmaceuticals industry. The Company is a producer and supplier of Active Pharmaceutical Ingredients (APIs), which are used in medications for diabetes. Vistin Pharma offering such products: Metformin HCl (API); Metformin DC (direct compressible granules); Customized Particle Distribution (PSD) and Premix (Metformin + MgSt, can be delivered on-request). The Company’s customers are pharmaceutical companies worldwide.
- Revenue in NOK (TTM)438.34m
- Net income in NOK56.23m
- Incorporated2015
- Employees77.00
- LocationVistin Pharma ASAOstensjoveien 27OSLO 0661NorwayNOR
- Phone+47 35984200
- Websitehttps://www.vistin.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arctic Bioscience AS | 33.75m | -45.51m | 271.45m | 20.00 | -- | 1.05 | -- | 8.04 | -1.79 | -1.79 | 1.33 | 10.19 | 0.1075 | 0.7025 | 2.93 | 1,687,501.00 | -14.50 | -- | -16.61 | -- | 28.96 | -- | -134.86 | -- | 2.53 | -- | 0.0079 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
Corline Biomedical AB | 21.50m | -4.52m | 276.82m | 13.00 | -- | 3.00 | -- | 12.87 | -0.2092 | -0.2092 | 0.9944 | 4.26 | 0.2089 | -- | 6.96 | 1,643,846.00 | -4.39 | -5.71 | -4.80 | -6.24 | 115.99 | 128.60 | -21.04 | -38.46 | -- | -235.63 | 0.00 | -- | 6.28 | 74.14 | -177.67 | -- | 62.51 | -- |
Enzymatica AB (publ) | 47.59m | -54.01m | 408.27m | 18.00 | -- | 4.83 | -- | 8.58 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
Magle Chemoswed Holding AB | 171.08m | 12.31m | 467.33m | 78.00 | 37.98 | 2.88 | 18.54 | 2.73 | 1.13 | 1.13 | 15.74 | 14.95 | 0.6068 | 0.493 | 8.30 | 2,179,628.00 | 4.36 | 2.52 | 5.86 | 3.52 | 90.58 | 85.67 | 7.19 | 3.92 | 0.6356 | 6.35 | 0.3081 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
Navamedic ASA | 511.15m | -11.45m | 590.97m | 45.00 | -- | 2.60 | 267.65 | 1.16 | -0.6671 | -0.6671 | 29.64 | 13.03 | 1.10 | 3.11 | 4.58 | 11,358,890.00 | -2.47 | 0.039 | -3.76 | 0.0635 | 38.27 | 38.33 | -2.24 | 0.038 | 0.7667 | 0.6584 | 0.3992 | -- | 33.98 | 22.72 | -88.77 | -2.53 | 59.60 | -- |
Orexo AB | 623.00m | -73.86m | 684.62m | 113.00 | -- | 11.00 | 117.30 | 1.10 | -2.13 | -2.13 | 17.98 | 1.78 | 0.6959 | 1.08 | 2.53 | 5,337,069.00 | -8.25 | -6.41 | -20.27 | -9.99 | 88.14 | 86.76 | -11.86 | -11.83 | 0.589 | 0.1386 | 0.8948 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
IRLAB Therapeutics AB | 5.71m | -158.29m | 698.34m | 28.00 | -- | 9.06 | -- | 122.22 | -3.03 | -3.03 | 0.1095 | 1.48 | 0.0274 | -- | 0.4652 | 218,384.60 | -75.97 | -27.12 | -94.23 | -30.42 | -1,952.47 | -72.18 | -2,770.38 | -155.57 | -- | -- | 0.2646 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
Moberg Pharma AB (publ) | 825.17k | -22.70m | 847.41m | 9.00 | -- | 1.33 | -- | 1,026.95 | -1.09 | -1.09 | 0.0379 | 21.63 | 0.0014 | -- | 0.2841 | -- | -3.81 | -- | -3.96 | -- | 60.00 | -- | -2,751.22 | -- | 1.73 | -- | 0.0073 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
Vistin Pharma ASA | 438.34m | 56.23m | 966.71m | 77.00 | 17.19 | 3.25 | 13.05 | 2.21 | 1.27 | 1.27 | 9.88 | 6.70 | 1.11 | 2.31 | 7.44 | 5,692,663.00 | 14.28 | 1.73 | 18.93 | 2.11 | 59.93 | 58.92 | 12.83 | 2.36 | 0.8536 | 32.96 | 0.0934 | -- | 51.35 | 16.95 | 1,066.84 | -- | -0.1922 | -- |
Infant Bacterial Therapeutics AB | 0.00 | -129.22m | 1.29bn | 9.00 | -- | 4.79 | -- | -- | -9.96 | -9.96 | 0.00 | 20.59 | 0.00 | -- | -- | 0.00 | -37.63 | -16.11 | -43.78 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
Photocure ASA | 512.45m | 4.82m | 1.58bn | 102.00 | 332.86 | 3.28 | 47.82 | 3.09 | 0.1755 | 0.1755 | 19.02 | 17.82 | 0.7215 | 0.9144 | 7.93 | 5,024,010.00 | 0.6789 | -3.06 | 0.7682 | -3.54 | 94.65 | 93.64 | 0.941 | -5.15 | 4.33 | -- | 0.00 | -- | 27.35 | 22.50 | 101.36 | -- | 49.83 | -- |
Probi AB | 611.37m | -605.79k | 3.44bn | 167.00 | -- | 2.40 | 35.62 | 5.63 | -0.0528 | -0.0528 | 53.32 | 125.16 | 0.3885 | 3.23 | 6.52 | 3,797,144.00 | -0.0385 | 4.64 | -0.0407 | 4.98 | 32.39 | 42.04 | -0.0991 | 9.83 | 6.22 | -- | 0.0353 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
Flerie AB | 109.02m | -56.84m | 3.68bn | 7.00 | -- | 1.06 | -- | 33.79 | -0.1037 | -0.1037 | 0.2028 | 0.443 | 0.3559 | -- | -- | 15,477,000.00 | -18.55 | -37.64 | -21.24 | -41.14 | -46.98 | -450.51 | -52.13 | -454.62 | -- | -- | 0.0086 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
Data as of Jul 04 2024. Currency figures normalised to Vistin Pharma ASA's reporting currency: Norwegian Krone NOK
11.82%Per cent of shares held by top holders
Holder | Shares | % Held |
---|---|---|
Holmen Fondsforvaltning ASas of 31 Mar 2023 | 3.52m | 7.94% |
MP Pensjon PKas of 31 Mar 2023 | 1.72m | 3.88% |
Data from 25 Jun 2024 - 25 Jun 2024Source: FactSet Research Systems Inc.